President Biden received a 56 percent approval rating in a recent Fox News poll. The number marks a slight increase from the 54 percent who approved of his performance in April and May. The poll also found 43 percent of voters disapprove of his performance. Sixty-four percent of those surveyed approved of Biden's handling of the coronavirus pandemic, including 4 in 10 Republicans and 9 in 10 Democrats, while 34 percent disapproved. Biden’s handling of the pandemic has been his best issue overall in polls. The high approval rating for the pandemic comes as many states have fully reopened for business and millions across the country have been fully vaccinated. In regard to the start of the pandemic, 60 percent in the poll said they believe the virus was leaked from a lab in China, with only 31 percent believing it occurred naturally. Although the lab leak theory used to be regarded as a conspiracy, new evidence has caused health officials to to take a second look. Biden has ordered the intelligence community to review the origins of the coronavirus. The poll surveyed 1,001 registered voters from June 19 to June 22. It has a margin of error of 3 percentage points.
Those are striking results in the details. But if you are an avid consumer of Fox News’s programming and online content, you’d be forgiven for not having heard about them. On Thursday morning, I noticed that the results, released Wednesday evening, didn’t appear on the Fox News homepage. Instead, there was a text link to a story about the poll generally, focused on a different question that dealt with the coronavirus pandemic. That story by Fox News’ Dana Blanton does include the Biden approval number — literally the last line in the story.
Fox News hosts have defended the results of a poll the network commissioned that shows a majority of Americans surveyed approve of Joe Biden’s performance as president so far. Former President Trump’s daughter-in-law, Lara Trump, pushed back on the poll on Fox News’ on air, calling the approval rating not “legitimate”. The poll showed Mr Biden with a 54 per cent approval rating. “Well, Fox News stands by the poll,” Fox & Friends co-host Steve Doocy said to Ms Trump. “I truly don’t believe that. I don’t think that is a legitimate number,” Ms Trump said, adding that she feels Mr Biden gets “totally coddled guys by the mainstream media, every time you see him, truly, asked a question by so many of these outlets, they’re these softball questions about ice cream and it really, they don’t push him on anything, they don’t follow up with him in the way we know they would with Donald Trump,” Ms Trump said when she heard the results of the Fox poll. She went to state that Biden receives “ glowing reviews all around from the mainstream media” and that those who answered the poll were “not getting the full picture” about the current president. “I cannot believe that anybody would have his approval rating anywhere over about negative five per cent at this point,” Ms Trump said about Mr Biden, who has led a relatively successful national Covid-19 vaccination roll out, passed some key legislation with a slim Senate majority and brought back international stability at talks with other world leaders at the G7 summit in Cornwall, England.
Tony, I know you cant think for yourself but try. How much does the Trump vaccine Covid results raise his overall number It is the only category that he is above his average
https://fortune.com/2020/11/09/pfizer-vaccine-funding-warp-speed-germany/ It’s said that success has many authors, and the encouraging data from Pfizer Inc.’s experimental COVID-19 vaccine had plenty of people in Washington lining up to take credit. Vice President Mike Pence was among Trump administration officials saying support from the government’s Operation Warp Speed program helped accelerate the development of the vaccine, which was found to be more than 90% effective in preventing symptomatic COVID-19 infections in an interim analysis. The truth is that Pfizer didn’t receive any funding from Operation Warp Speed for the development, clinical trial and manufacturing of the vaccine. Rather, its partner, BioNTech SE, has received money -- from the German government. BioNTech is credited for contributing the messenger RNA technology, which prompts the body to make a key protein from the virus, creating an immune response. The biotechnology company already had a history of working with Pfizer on influenza vaccines, and in March they clinched a deal to co-develop a shot to prevent against COVID-19 at research sites both in the U.S. and Germany. The two companies began human testing of the vaccine in April, before the existence of Operation Warp Speed was revealed publicly. Berlin gave the German company $445 million in an agreement in September to help accelerate the vaccine by building out manufacturing and development capacity in its home market.
Obama funded Messenger RNA vaccine development that the vaccines are based on. https://investors.modernatx.com/new...moderna-therapeutics-grant-25-million-develop CAMBRIDGE, Mass., October 2, 2013—Moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats. Messenger RNA therapeutics™ can be designed to tap directly into the body’s natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, Moderna’s messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies. “We are honored to be chosen by DARPA for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases,” said Stéphane Bancel, president and founding CEO of Moderna. “We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team’s progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area.” This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million “seedling” grant from DARPA in March to begin work on the project. This grant is part of a DARPA program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown. For more information about DARPA, visit http://www.darpa.mil/about-us/about-darpa.